Clinical Trial Update: Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates whether Acetyl-L-Carnitine can prevent Sagopilone-induced neurotoxicity in prostate and ovarian cancer patients. The study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Prostate Cancer

Drugs mentioned

• Acetyl-L-carnitine (N-acetyl-L-carnitine)
• Sagopilone (Sagopilone)

Snippet

Sponsor: Bayer | Conditions: Prostate Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED